• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Plasminogen activator inhibitor‐1 as regulator of tumor‐initiating cell properties in head and neck cancers
ConclusionThe inhibition of PAI‐1 by PAI‐039 or siRNA could suppress head and neck cancer‐TICs within head and neck cancer cell lines through the downregulation of Sox2. © 2015 Wiley Periodicals, Inc. Head Neck, 2015
Source: Head and Neck - July 16, 2015 Category: ENT & OMF Authors: Yueh‐Chun Lee, Cheng‐Chia Yu, Chih Lan, Che‐Hsin Lee, Hsueh‐Te Lee, Yu‐Liang Kuo, Po‐Hui Wang, Wen‐Wei Chang Tags: Original Article Source Type: research

Epidermal growth factor receptor inhibition by anti‐CD147 therapy in cutaneous squamous cell carcinoma
ConclusionInhibition and downregulation of CD147 in cutaneous SCC resulted in suppression of the malignant phenotype in vitro and in vivo, which may be mediated in part by an alteration in EGFR expression. As a result, CD147 may serve as a potential therapeutic target for advanced cutaneous SCC. © 2014 Wiley Periodicals, Inc. Head Neck, 2015
Source: Head and Neck - June 16, 2015 Category: ENT & OMF Authors: John W. Frederick, Larissa Sweeny, Yolanda Hartman, Tong Zhou, Eben L. Rosenthal Tags: Original Article Source Type: research

Plasminogen activator inhibitor‐1 regulates tumor initiating cell properties in head and neck cancers
Conclusion The inhibition of PAI‐1 by PAI‐039 or siRNA could suppress HNC‐TICs within HNC cell lines through the down‐regulation of Sox2. This article is protected by copyright. All rights reserved.
Source: Head and Neck - May 1, 2015 Category: ENT & OMF Authors: Yueh‐Chun Lee, Cheng‐Chia Yu, Chih Lan, Che‐Hsin Lee, Hsueh‐Te Lee, Yu‐Liang Kuo, Po‐Hui Wang, Wen‐Wei Chang Tags: Original Article Source Type: research

EGFR inhibition by anti‐CD147 therapy in Cutaneous Squamous cell Carcinoma
Conclusions: Inhibition and down‐regulation of CD147 in cSCC resulted in suppression of the malignant phenotype in vitro and in vivo which may be mediated in part by an alteration in EGFR expression. As a result, CD147 may serve as a potential therapeutic target for advanced cSCC. Head Neck, 2014
Source: Head and Neck - October 1, 2014 Category: ENT & OMF Authors: John W. Frederick, Larissa Sweeny, Yolanda Hartman, Tong Zhou, Eben L. Rosenthal Tags: Original Article Source Type: research

Inhibition of myeloid cell leukemia‐1: Association with sorafenib‐induced apoptosis in human mucoepidermoid carcinoma cells and tumor xenograft
ConclusionTaken together, these findings suggest that sorafenib can be a good anticancer drug candidate for the treatment of MEC. © 2014 Wiley Periodicals, Inc. Head Neck, 2014
Source: Head and Neck - July 19, 2014 Category: ENT & OMF Authors: Hyun‐Ju Yu, Ji‐Ae Shin, Ji‐Youn Jung, Jeong‐Seok Nam, In‐Sun Hong, Nam‐Pyo Cho, Sung‐Dae Cho Tags: Original Article Source Type: research

In vitro study of normoxic epidermal growth factor receptor–induced hypoxia‐inducible factor‐1‐alpha, vascular endothelial growth factor, and BNIP3 expression in head and neck squamous cell carcinoma cell lines: Implications for anti–epidermal growth factor receptor therapy
ConclusionThe search for molecular predictors of sensitivity to gefitinib in HNSCC should be extended to the activation status of EGFR‐downstream pathways, phosphorylated protein kinase B, pMAPK, and HIF‐1α. © 2014 Wiley Periodicals, Inc. Head Neck, 2014
Source: Head and Neck - July 7, 2014 Category: ENT & OMF Authors: Pablo Secades, Inés Saenz Santa‐María, Anna Merlo, Carlos Suarez, María‐Dolores Chiara Tags: Original Article Source Type: research

In vitro study of normoxic epidermal growth factor (EGF)‐induced HIF‐1α, VEGF and BNIP3 expression in head and neck squamous cell carcinoma cell lines: implications for anti‐EGFR therapy
Conclusions The search for molecular predictors of sensitivity to gefitinib in HNSCC should be extended to the activation status of EGFR‐downstream pathways, pAkt, pMAPK, and HIF‐1α. Head Neck, 2014
Source: Head and Neck - May 2, 2014 Category: ENT & OMF Authors: Pablo Secades, Inés Saenz de Santamaría, Anna Merlo, Carlos Suarez, María‐Dolores Chiara Tags: Original Article Source Type: research

HRAS mutations and resistance to the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in head and neck squamous cell carcinoma cells
Conclusion: Activating HRAS mutations can confer erlotinib resistance in an HRAS mutant HNSCC cell line. Head Neck, 2013.
Source: Head and Neck - September 30, 2013 Category: ENT & OMF Authors: J. Hun Hah, Mei Zhao, Curtis R. Pickering, Mitchell J. Frederick, Genevieve A. Andrews, Samar A. Jasser, David R. Fooshee, Zvonimir L. Milas, Chad Galer, Daisuke Sano, William N. William, Edward Kim, John Heymach, Lauren A. Byers, Vali Papadimitrakopoulou Tags: Research Article Source Type: research